Rhizen Pharmaceuticals S.A. Announces Presentations on Tenalisib (RP6530) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
29 mai 2018 07h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, May 29, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., a clinical-stage biotechnology company developing Tenalisib (RP6530), a highly selective and orally...